Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Activating KRAS mutations are common in solid tumors like lung, colorectal, and pancreatic cancers.
• Mutated KRAS impacts survival in non-small cell lung cancer (NSCLC) and signifies a more aggressive disease.
• Targeted therapies for KRAS mutations are crucial due to their prevalence and prognostic significance.

Purpose of the Study:

• To review KRAS mutation prevalence, subtypes, and occurrence in invasive mucinous adenocarcinomas.
• To discuss novel drug delivery options and the current status of KRAS inhibitors.
• To explore resistance mechanisms, combination strategies, and multitargeted approaches for KRAS-driven NSCLC.

Main Methods:

• Literature review of KRAS mutation prevalence and targeted therapies.
• Analysis of current clinical trial data for KRAS G12C inhibitors.
• Discussion of resistance mechanisms and combination treatment strategies.

Main Results:

• KRAS G12C inhibitors (sotorasib, adagrasib) are approved for pre-treated NSCLC patients.
• Numerous KRAS G12C inhibitors are in clinical trials, as single agents or combinations.
• Research is ongoing to understand and overcome resistance to KRAS-targeted therapies.

Conclusions:

• Targeting KRAS G12C represents a significant advancement in cancer therapy.
• Understanding resistance mechanisms is key to optimizing combination and multitargeted treatment strategies.
• Further research is needed to improve efficacy and broaden the application of KRAS inhibitors.